| Original language | English |
|---|---|
| DOIs | |
| Publication status | Published - Jun 2021 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
A real-world experience of second-line nivolumab in mesothelioma patients during the COVID-19 pandemic
- Matt Church
Research output: Contribution to conference › Abstract › peer-review